GALDERMA-GROUP-AG
Galderma Group AG (SWX:GALD):
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
Galderma Group AG, the pure-play dermatology category leader, today announces the pricing of its Initial Public Offering at CHF 53 per share, at the top of the announced price range. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange tomorrow, March 22, 2024.
To access the full announcement on the public offering of securities of Galderma Group AG in Switzerland, for those legally permitted, please visit www.galderma.com/intentiontofloat.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience and Sculptra in Injectable Aesthetics; Cetaphil and Alastin in Dermatological Skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac and Loceryl in Therapeutic Dermatology. For more information: www.galderma.com.
The securities of Galderma Group AG have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320563126/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-ANDERSEN-GLOBAL27.7.2024 11:39:35 CEST | Pressemeddelelse
Andersen Global tilføjer værdiansættelseskapacitet i Bulgarien
MI-LINEAGE26.7.2024 23:20:27 CEST | Press release
Lineage Announces Closing of Initial Public Offering
TN-LEDGER26.7.2024 17:16:33 CEST | Press release
Introducing LEDGER FLEX — Easy, Secure Self-Custody, Free From Compromise
CA-LAMBDATEST26.7.2024 17:01:33 CEST | Press release
LambdaTest Unveils Live Inspect for Enhanced App Automation Testing
RADICO-KHAITAN26.7.2024 15:05:31 CEST | Press release
Radico Khaitan comes onboard as the Official Partner for the first India House at The Paris 2024 Olympics
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom